Skip Navigation

Annals of Oncology 2009 20(Supplement 4):iv19-iv20; doi:10.1093/annonc/mdp116
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Balmaña, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Balmaña, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

ESMO clinical recommendations

BRCA in breast cancer: ESMO Clinical Recommendations

J. Balmaña1, O. Díez2, M. Castiglione3 and On behalf of the ESMO Guidelines Working Group*

1 Department of Medical Oncology
2 Department of Genetics, Vall d'Hebron University Hospital, Barcelona, Spain
3 Institute of Social and Preventive Medicine (ISPM), University of Geneva, Geneva, Switzerland

* Correspondence to: ESMO Guidelines Working Group, ESMO Head Office, Via L. Taddei 4, CH-6962 Viganello-Lugano, Switzerland; E-mail: clinicalrecommendations@esmo.org

The first 10% of the full text of this article appears below.


   prevalence and penetrance of BRCA mutations
 
Familial susceptibility to breast cancer accounts for ~25% of all breast cancer cases. In familial breast cancer, mutations in the BRCA1, BRCA2, CHEK2, TP53 and PTEN genes account for ~5–10% of breast and ovarian cancer cases overall. The prevalence of BRCA1 or BRCA2 mutations varies considerably between ethnic groups and geographical . . . [Full Text of this Article]


   referral for BRCA testing
 

   mutation detection
 

   risk reduction: non-surgical preventive options
 
surveillance
chemoprevention

   risk reduction: prophylactic surgical options
 
prophylactic bilateral mastectomy
prophylactic bilateral salpingo-oophorectomy

   breast cancer treatment
 

   note
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?